From the crop of big-cap biotech companies, Gilead Sciences (GILD Quote)CEO John Martin deserves the most praise for continuous excellence, while Amgen(AMGN Quote) CEO Kevin Sharer wins comeback of the year honors.
Two other biotech chiefs are also deserving of mention. First, Medivation's(MDVN Quote) David Hung negotiated a fat $250 million upfront payment from Pfizer for co-development rights to his Alzheimer's drug Dimebon. Second, a conditional honorable mention goes to Brian Pereira of AMAG Pharmaceuticals(AMAG Quote). If the FDA approves AMAG's iron replacement therapy on Dec. 30, Meldrum may have to share the Best CEO trophy. Then again, if the FDA delays approval, Pereira might find himself an early contender for worst biotech CEO of 2009.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,337.05 | 1,095.94 | 2,183.73 | 34.23 |
Oil *
72.45
|
|
UP
51.08
|
UP
4.01
|
UP
10.74
|
UP
0.31
|
10 Yr
3.42%
SPDR Gold
110.84
|
|
+0.50%
|
+0.37%
|
+0.49%
|
+0.91%
|
Data delayed 20 minutes |
